ctDNA Biomarkers in INTRIGUE: Understanding Resistance Patterns

EP: 1.Optimizing TKI Selection and Sequencing Strategies in Advanced GIST Beyond First-Line Therapy

EP: 2.Biological Mechanisms of GIST Resistance and Tumor Heterogeneity

EP: 3.Monitoring Tumor Heterogeneity and Detecting Resistance

EP: 4.Post-Imatinib Progression: Decision Factors and Treatment Options

EP: 5.INVICTUS Trial: Ripretinib in Fourth-Line Setting

EP: 6.INTRIGUE Trial: Key Findings in Second-Line Setting

Now Viewing

EP: 7.ctDNA Biomarkers in INTRIGUE: Understanding Resistance Patterns

EP: 8.Managing Adverse Events With Different TKIs

EP: 9.Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches

EP: 10.Practical Recommendations for Community Oncologists

Video content above is prompted by the following:

• A follow-up exploratory analysis of the INTRIGUE trial investigated ctDNA biomarkers to better understand resistance patterns. Could you discuss the key insights from this analysis? How might these mutation-specific findings change our approach to molecular testing before selecting a second-line agent, and what are the practical implications for implementing this more personalized approach in clinical practice?